{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T02:55:13Z","timestamp":1769309713198,"version":"3.49.0"},"reference-count":127,"publisher":"Bentham Science Publishers Ltd.","issue":"40","funder":[{"DOI":"10.13039\/501100003399","name":"Shanghai Municipal committee of Science and Technology","doi-asserted-by":"publisher","award":["12140901802"],"award-info":[{"award-number":["12140901802"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81201988"],"award-info":[{"award-number":["81201988"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Oncolytic viruses, as novel biological anti-tumor agents, provide anti-tumor therapeutic effects by\ndifferent mechanisms including directly selective tumor cell lysis and secondary systemic anti-tumor immune\nresponses. Some wide-type and genetically engineered oncolytic viruses have been applied in clinical trials.\nAmong them, T-Vec has a significant therapeutic effect on melanoma patients and received the approval of the\nUS Food and Drug Administration (FDA) as the first oncolytic virus to treat cancer in the US. However, the\nmechanisms of virus interaction with tumor and immune systems have not been clearly elucidated and there are\nstill no \u201cgold standards\u201d for instructions of virotherapy in clinical trials. This Review collected the recent clinical\ntrials data from 2005 to summarize the basic oncolytic viruses biology, describe the application in recent clinical\ntrials, and discuss the challenges in the application of oncolytic viruses in clinical trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666191104090544","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T10:22:01Z","timestamp":1572862921000},"page":"4251-4263","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-8755","authenticated-orcid":true,"given":"Yuhui","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Spine Surgery, Renji Hospital, Medical School, Shanghai Jiaotong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-0976","authenticated-orcid":true,"given":"Zhuoming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.tips.2007.05.005","volume":"28","author":"Russell S.J.","year":"2007","unstructured":"Russell S.J.; Peng K.W.; Viruses as anticancer drugs. Trends Pharmacol Sci 2007,28(7),326-333","journal-title":"Trends Pharmacol Sci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","volume":"15","author":"Kelly E.","year":"2007","unstructured":"Kelly E.; Russell S.J.; History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007,15(4),651-659","journal-title":"Mol Ther"},{"key":"ref=3","first-page":"314","volume":"8","author":"Roberts M.S.","year":"2006","unstructured":"Roberts M.S.; Lorence R.M.; Groene W.S.; Bamat M.K.; Naturally oncolytic viruses. Curr Opin Mol Ther 2006,8(4),314-321","journal-title":"Curr Opin Mol Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/v10080421","volume":"10","author":"Bourhill T.","year":"2018","unstructured":"Bourhill T.; Mori Y.; Rancourt D.E.; Shmulevitz M.; Johnston R.N.; Going (Reo)viral: factors promoting successful reoviral oncolytic infection. Viruses 2018,10(8),10","journal-title":"Viruses"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.addr.2009.03.013","volume":"61","author":"Dorer D.E.","year":"2009","unstructured":"Dorer D.E.; Nettelbeck D.M.; Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 2009,61(7-8),554-571","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.ymthe.2017.03.026","volume":"25","author":"Russell S.J.","year":"2017","unstructured":"Russell S.J.; Peng K.W.; Oncolytic virotherapy: a contest between apples and oranges. Mol Ther 2017,25(5),1107-1116","journal-title":"Mol Ther"},{"key":"ref=7","first-page":"3","volume":"25","author":"Fukazawa T.","year":"2010","unstructured":"Fukazawa T.; Matsuoka J.; Yamatsuji T.; Maeda Y.; Durbin M.L.; Naomoto Y.; Adenovirus-mediated cancer gene therapy and virotherapy. (Review) Int J Mol Med 2010,25(1),3-10","journal-title":"Int J Mol Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s12253-012-9548-2","volume":"18","author":"Zeyaullah M.","year":"2012","unstructured":"Zeyaullah M.; Patro M.; Ahmad I.; Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 2012,18(4),771-781","journal-title":"Pathol Oncol Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.canlet.2007.02.002","volume":"254","author":"V\u00e4h\u00e4-Koskela M.J.","year":"2007","unstructured":"V\u00e4h\u00e4-Koskela M.J.; Heikkil\u00e4 J.E.; Hinkkanen A.E.; Oncolytic viruses in cancer therapy. Cancer Lett 2007,254(2),178-216","journal-title":"Cancer Lett"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/mt.2008.288","volume":"17","author":"Kelly E.J.","year":"2009","unstructured":"Kelly E.J.; Russell S.J.; MicroRNAs and the regulation of vector tropism. Mol Ther 2009,17(3),409-416","journal-title":"Mol Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrg2141","volume":"8","author":"Waehler R.","year":"2007","unstructured":"Waehler R.; Russell S.J.; Curiel D.T.; Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007,8(8),573-587","journal-title":"Nat Rev Genet"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.0954-6820.1958.tb17327.x","volume":"338","author":"Pelner L.","year":"1958","unstructured":"Pelner L.; Fowler G.A.; Nauts H.C.; Effects of concurrent infections and their toxins on the course of leukemia. Acta Med Scand Suppl 1958,338,1-47","journal-title":"Acta Med Scand Suppl"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trsl.2012.11.003","volume":"161","author":"Murphy A.M.","year":"2013","unstructured":"Murphy A.M.; Rabkin S.D.; Current status of gene therapy for brain tumors. Transl Res 2013,161(4),339-354","journal-title":"Transl Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.coviro.2015.03.009","volume":"13","author":"Jiang H.","year":"2015","unstructured":"Jiang H.; Gomez-Manzano C.; Rivera-Molina Y.; Lang F.F.; Conrad C.A.; Fueyo J.; Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. Curr Opin Virol 2015,13,33-39","journal-title":"Curr Opin Virol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"Bischoff J.R.","year":"1996","unstructured":"Bischoff J.R.; Kirn D.H.; Williams A.; An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996,274(5286),373-376","journal-title":"Science"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"7742","DOI":"10.1073\/pnas.89.16.7742","volume":"89","author":"Rao L.","year":"1992","unstructured":"Rao L.; Debbas M.; Sabbatini P.; Hockenbery D.; Korsmeyer S.; White E.; The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 1992,89(16),7742-7746","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.onc.1203251","volume":"19","author":"Fueyo J.","year":"2000","unstructured":"Fueyo J.; Gomez-Manzano C.; Alemany R.; A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000,19(1),2-12","journal-title":"Oncogene"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","volume":"2","author":"Chiocca E.A.","year":"2014","unstructured":"Chiocca E.A.; Rabkin S.D.; Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2014,2(4),295-300","journal-title":"Cancer Immunol Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.2174\/138920112800958814","volume":"13","author":"Kaur B.","year":"2012","unstructured":"Kaur B.; Chiocca E.A.; Cripe T.P.; Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol 2012,13(9),1842-1851","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1172\/JCI80713","volume":"125","author":"Nakashima H.","year":"2015","unstructured":"Nakashima H.; Kaufmann J.K.; Wang P.Y.; Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J Clin Invest 2015,125(11),4269-4280","journal-title":"J Clin Invest"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ccr.2008.12.006","volume":"15","author":"Alcantara Llaguno S.","year":"2009","unstructured":"Alcantara Llaguno S.; Chen J.; Kwon C.H.; Malignant astrocytomas originate from neural stem\/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009,15(1),45-56","journal-title":"Cancer Cell"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cancers10120492","volume":"10","author":"Stepanenko A.A.","year":"2018","unstructured":"Stepanenko A.A.; Chekhonin V.P.; Recent advances in oncolytic virotherapy and immunotherapy for glioblastoma: a glimmer of hope in the search for an effective therapy? Cancers (Basel) 2018,10(12),10","journal-title":"Cancers (Basel)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/sj.cgt.7700750","volume":"12","author":"Conrad C.","year":"2005","unstructured":"Conrad C.; Miller C.R.; Ji Y.; Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 2005,12(3),284-294","journal-title":"Cancer Gene Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/sj.onc.1207321","volume":"23","author":"Gomez-Manzano C.","year":"2004","unstructured":"Gomez-Manzano C.; Balague C.; Alemany R.; A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 2004,23(10),1821-1828","journal-title":"Oncogene"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","year":"2008","unstructured":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature Cancer Genome Atlas Research Network2008,455(7216),1061-1068","journal-title":"Nature"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"Bergelson J.M.","year":"1997","unstructured":"Bergelson J.M.; Cunningham J.A.; Droguett G.; Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997,275(5304),1320-1323","journal-title":"Science"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1006\/viro.2000.0324","volume":"271","author":"Martino T.A.","year":"2000","unstructured":"Martino T.A.; Petric M.; Weingartl H.; The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus. Virology 2000,271(1),99-108","journal-title":"Virology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.addr.2005.01.007","volume":"57","author":"Coyne C.B.","year":"2005","unstructured":"Coyne C.B.; Bergelson J.M.; CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev 2005,57(6),869-882","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","volume":"95","author":"Fueyo J.","year":"2003","unstructured":"Fueyo J.; Alemany R.; Gomez-Manzano C.; Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003,95(9),652-660","journal-title":"J Natl Cancer Inst"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097407","volume":"9","author":"Jiang H.","year":"2014","unstructured":"Jiang H.; Clise-Dwyer K.; Ruisaard K.E.; Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 2014,9(5)","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-4781(02)00249-X","volume":"1575","author":"Barnett B.G.","year":"2002","unstructured":"Barnett B.G.; Crews C.J.; Douglas J.T.; Targeted adenoviral vectors. Biochim Biophys Acta 2002,1575(1-3),1-14","journal-title":"Biochim Biophys Acta"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.2353\/ajpath.2009.090028","volume":"175","author":"Kaur S.","year":"2009","unstructured":"Kaur S.; Kenny H.A.; Jagadeeswaran S.; beta3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol 2009,175(5),2184-2196","journal-title":"Am J Pathol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","volume":"73","author":"Wickham T.J.","year":"1993","unstructured":"Wickham T.J.; Mathias P.; Cheresh D.A.; Nemerow G.R.; Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993,73(2),309-319","journal-title":"Cell"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"10274","DOI":"10.1128\/JVI.74.22.10274-10286.2000","volume":"74","author":"Shayakhmetov D.M.","year":"2000","unstructured":"Shayakhmetov D.M.; Lieber A.; Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol 2000,74(22),10274-10286","journal-title":"J Virol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/cas.12267","volume":"104","author":"Takagi-Kimura M.","year":"2013","unstructured":"Takagi-Kimura M.; Yamano T.; Tamamoto A.; Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Cancer Sci 2013,104(11),1433-1439","journal-title":"Cancer Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.3390\/v7112923","volume":"7","author":"Uusi-Kerttula H.","year":"2015","unstructured":"Uusi-Kerttula H.; Hulin-Curtis S.; Davies J.; Parker A.L.; Oncolytic Adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 2015,7(11),6009-6042","journal-title":"Viruses"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.virusres.2018.08.012","volume":"257","author":"Stepanenko A.A.","year":"2018","unstructured":"Stepanenko A.A.; Chekhonin V.P.; Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: focus on fiber chimerism and mosaicism, hexon and pIX. Virus Res 2018,257,40-51","journal-title":"Virus Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nrc2545","volume":"9","author":"Kirn D.H.","year":"2009","unstructured":"Kirn D.H.; Thorne S.H.; Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009,9(1),64-71","journal-title":"Nat Rev Cancer"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12275-015-5041-4","volume":"53","author":"Kim M.","year":"2015","unstructured":"Kim M.; Replicating poxviruses for human cancer therapy. J Microbiol 2015,53(4),209-218","journal-title":"J Microbiol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s12026-011-8211-4","volume":"50","author":"Thorne S.H.","year":"2011","unstructured":"Thorne S.H.; Immunotherapeutic potential of oncolytic vaccinia virus. Immunol Res 2011,50(2-3),286-293","journal-title":"Immunol Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/mt.2011.276","volume":"20","author":"Parato K.A.","year":"2012","unstructured":"Parato K.A.; Breitbach C.J.; Le Boeuf F.; The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012,20(4),749-758","journal-title":"Mol Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.virol.2005.09.037","volume":"344","author":"Moss B.","year":"2006","unstructured":"Moss B.; Poxvirus entry and membrane fusion. Virology 2006,344(1),48-54","journal-title":"Virology"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.4049\/jimmunol.172.10.6265","volume":"172","author":"Xu R.","year":"2004","unstructured":"Xu R.; Johnson A.J.; Liggitt D.; Bevan M.J.; Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004,172(10),6265-6271","journal-title":"J Immunol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"10010","DOI":"10.1128\/JVI.00601-06","volume":"80","author":"Tang J.","year":"2006","unstructured":"Tang J.; Murtadha M.; Schnell M.; Eisenlohr L.C.; Hooper J.; Flomenberg P.; Human T-cell responses to vaccinia virus envelope proteins. J Virol 2006,80(20),10010-10020","journal-title":"J Virol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","volume":"14","author":"Kim J.H.","year":"2006","unstructured":"Kim J.H.; Oh J.Y.; Park B.H.; Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006,14(3),361-370","journal-title":"Mol Ther"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/OV.S189832","volume":"8","author":"Tang B.","year":"2019","unstructured":"Tang B.; Guo Z.S.; Bartlett D.L.; A cautionary note on the selectivity of oncolytic poxviruses. Oncolytic Virother 2019,8,3-8","journal-title":"Oncolytic Virother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","volume":"14","author":"Gulley J.L.","year":"2008","unstructured":"Gulley J.L.; Arlen P.M.; Tsang K.Y.; Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008,14(10),3060-3069","journal-title":"Clin Cancer Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/00002371-200009000-00007","volume":"23","author":"Scholl S.M.","year":"2000","unstructured":"Scholl S.M.; Balloul J.M.; Le Goc G.; Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000,23(5),570-580","journal-title":"J Immunother"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","volume":"19","author":"Heo J.","year":"2013","unstructured":"Heo J.; Reid T.; Ruo L.; Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013,19(3),329-336","journal-title":"Nat Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.antiviral.2006.04.002","volume":"71","author":"Whitley R.J.","year":"2006","unstructured":"Whitley R.J.; Herpes simplex encephalitis: adolescents and adults. Antiviral Res 2006,71(2-3),141-148","journal-title":"Antiviral Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/mto.2015.10","volume":"2","author":"Peters C.","year":"2015","unstructured":"Peters C.; Rabkin S.D.; Designing herpes viruses as oncolytics. Mol Ther Oncolytics 2015,2,2","journal-title":"Mol Ther Oncolytics"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.2741\/2823","volume":"13","author":"Todo T.","year":"2008","unstructured":"Todo T.; Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 2008,13,2060-2064","journal-title":"Front Biosci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fmicb.2014.00303","volume":"5","author":"Ning J.","year":"2014","unstructured":"Ning J.; Wakimoto H.; Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy. Front Microbiol 2014,5,303","journal-title":"Front Microbiol"},{"key":"ref=54","first-page":"a57","volume":"11","author":"Tyler K.L.","year":"2004","unstructured":"Tyler K.L.; Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including mollaret\u2019s. Herpes 2004,11(Suppl. 2),a57-a64","journal-title":"Herpes"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1073\/pnas.94.3.843","volume":"94","author":"He B.","year":"1997","unstructured":"He B.; Gross M.; Roizman B.; The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1997,94(3),843-848","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1158\/0008-5472.CAN-08-3886","volume":"69","author":"Wakimoto H.","year":"2009","unstructured":"Wakimoto H.; Kesari S.; Farrell C.J.; Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009,69(8),3472-3481","journal-title":"Cancer Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1128\/JVI.00017-12","volume":"86","author":"Kanai R.","year":"2012","unstructured":"Kanai R.; Zaupa C.; Sgubin D.; Effect of \u03b334.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol 2012,86(8),4420-4431","journal-title":"J Virol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"Liu B.L.","year":"2003","unstructured":"Liu B.L.; Robinson M.; Han Z.Q.; ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003,10(4),292-303","journal-title":"Gene Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/mthe.2000.0130","volume":"2","author":"Toda M.","year":"2000","unstructured":"Toda M.; Martuza R.L.; Rabkin S.D.; Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther 2000,2(4),324-329","journal-title":"Mol Ther"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1158\/1541-7786.MCR-12-0157","volume":"10","author":"Maitra R.","year":"2012","unstructured":"Maitra R.; Ghalib M.H.; Goel S.; Reovirus: a targeted therapeutic-progress and potential. Mol Cancer Res 2012,10(12),1514-1525","journal-title":"Mol Cancer Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-1-4939-2727-2_12","volume":"1317","author":"Thirukkumaran C.","year":"2015","unstructured":"Thirukkumaran C.; Morris D.G.; Oncolytic viral therapy using reovirus. Methods Mol Biol 2015,1317,187-223","journal-title":"Methods Mol Biol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1182\/bloodadvances.2018025593","volume":"3","author":"Thirukkumaran C.M.","year":"2019","unstructured":"Thirukkumaran C.M.; Shi Z.Q.; Nuovo G.J.; Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. Blood Adv 2019,3(5),797-812","journal-title":"Blood Adv"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"7695","DOI":"10.1128\/JVI.67.12.7695-7700.1993","volume":"67","author":"Thomis D.C.","year":"1993","unstructured":"Thomis D.C.; Samuel C.E.; Mechanism of interferon action: evidence for intermolecular autophosphorylation and autoactivation of the interferon-induced, RNA-dependent protein kinase PKR. J Virol 1993,67(12),7695-7700","journal-title":"J Virol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1128\/MMBR.00027-06","volume":"70","author":"Garc\u00eda M.A.","year":"2006","unstructured":"Garc\u00eda M.A.; Gil J.; Ventoso I.; Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 2006,70(4),1032-1060","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","volume":"17","author":"Strong J.E.","year":"1998","unstructured":"Strong J.E.; Coffey M.C.; Tang D.; Sabinin P.; Lee P.W.; The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998,17(12),3351-3362","journal-title":"EMBO J"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00430-010-0153-2","volume":"199","author":"Reuter D.","year":"2010","unstructured":"Reuter D.; Schneider-Schaulies J.; Measles virus infection of the CNS: human disease, animal models, and approaches to therapy. Med Microbiol Immunol (Berl) 2010,199(3),261-271","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/13550280390193993","volume":"9","author":"Schneider-Schaulies J.","year":"2003","unstructured":"Schneider-Schaulies J.; Meulen Vt, Schneider-Schaulies S. Measles infection of the central nervous system. J Neurovirol 2003,9(2),247-252","journal-title":"J Neurovirol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"8530","DOI":"10.1128\/JVI.00593-06","volume":"80","author":"Iankov I.D.","year":"2006","unstructured":"Iankov I.D.; Pandey M.; Harvey M.; Griesmann G.E.; Federspiel M.J.; Russell S.J.; Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 2006,80(17),8530-8540","journal-title":"J Virol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3892\/ijo.2016.3675","volume":"49","author":"Ellerhoff T.P.","year":"2016","unstructured":"Ellerhoff T.P.; Berchtold S.; Venturelli S.; Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus. Int J Oncol 2016,49(5),1931-1944","journal-title":"Int J Oncol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1128\/JVI.71.6.4736-4743.1997","volume":"71","author":"Shafren D.R.","year":"1997","unstructured":"Shafren D.R.; Dorahy D.J.; Ingham R.A.; Burns G.F.; Barry R.D.; Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 1997,71(6),4736-4743","journal-title":"J Virol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00430-003-0193-y","volume":"193","author":"Selinka H.C.","year":"2004","unstructured":"Selinka H.C.; Wolde A.; Sauter M.; Kandolf R.; Klingel K.; Virus-receptor interactions of coxsackie B viruses and their putative influence on cardiotropism. Med Microbiol Immunol (Berl) 2004,193(2-3),127-131","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jmv.20184","volume":"74","author":"Orthopoulos G.","year":"2004","unstructured":"Orthopoulos G.; Triantafilou K.; Triantafilou M.; Coxsackie B viruses use multiple receptors to infect human cardiac cells. J Med Virol 2004,74(2),291-299","journal-title":"J Med Virol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1158\/1078-0432.CCR-0690-3","volume":"10","author":"Shafren D.R.","year":"2004","unstructured":"Shafren D.R.; Au G.G.; Nguyen T.; Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 2004,10(1 Pt 1),53-60","journal-title":"Clin Cancer Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/OV.S56322","volume":"3","author":"Bradley S.","year":"2014","unstructured":"Bradley S.; Jakes A.D.; Harrington K.; Pandha H.; Melcher A.; Errington-Mais F.; Applications of coxsackievirus A21 in oncology. Oncolytic Virother 2014,3,47-55","journal-title":"Oncolytic Virother"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2018.02.001","volume":"9","author":"Annels N.E.","year":"2018","unstructured":"Annels N.E.; Arif M.; Simpson G.R.; Oncolytic immunotherapy for bladder cancer using coxsackie A21 virus. Mol Ther Oncolytics 2018,9,1-12","journal-title":"Mol Ther Oncolytics"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","volume":"72","author":"Miyamoto S.","year":"2012","unstructured":"Miyamoto S.; Inoue H.; Nakamura T.; Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res 2012,72(10),2609-2621","journal-title":"Cancer Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3389\/fimmu.2017.00555","volume":"8","author":"Guo Z.S.","year":"2017","unstructured":"Guo Z.S.; Liu Z.; Kowalsky S.; Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives. Front Immunol 2017,8,555","journal-title":"Front Immunol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fbioe.2015.00055","volume":"3","author":"Angelova A.L.","year":"2015","unstructured":"Angelova A.L.; Geletneky K.; N\u00fcesch J.P.; Rommelaere J.; Tumor selectivity of oncolytic parvoviruses: from in vitro and animal models to cancer patients. Front Bioeng Biotechnol 2015,3,55","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fonc.2017.00093","volume":"7","author":"Angelova A.L.","year":"2017","unstructured":"Angelova A.L.; Witzens-Harig M.; Galabov A.S.; Rommelaere J.; The oncolytic virotherapy era in cancer management: prospects of applying H-1 parvovirus to treat blood and solid cancers. Front Oncol 2017,7,93","journal-title":"Front Oncol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2217\/fvl.14.103","volume":"10","author":"Luo Y.","year":"2015","unstructured":"Luo Y.; Qiu J.; Human parvovirus B19: a mechanistic overview of infection and DNA replication. Future Virol 2015,10(2),155-167","journal-title":"Future Virol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"12766","DOI":"10.1128\/JVI.02333-13","volume":"87","author":"Luo Y.","year":"2013","unstructured":"Luo Y.; Kleiboeker S.; Deng X.; Qiu J.; Human parvovirus B19 infection causes cell cycle arrest of human erythroid progenitors at late S phase that favors viral DNA replication. J Virol 2013,87(23),12766-12775","journal-title":"J Virol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cytogfr.2010.02.011","volume":"21","author":"Rommelaere J.","year":"2010","unstructured":"Rommelaere J.; Geletneky K.; Angelova A.L.; Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010,21(2-3),185-195","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12985-014-0223-y","volume":"12","author":"Marchini A.","year":"2015","unstructured":"Marchini A.; Bonifati S.; Scott E.M.; Angelova A.L.; Rommelaere J.; Oncolytic parvoviruses: from basic virology to clinical applications. Virol J 2015,12,6","journal-title":"Virol J"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.ymthe.2017.08.016","volume":"25","author":"Geletneky K.","year":"2017","unstructured":"Geletneky K.; Hajda J.; Angelova A.L.; Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I\/IIa glioblastoma trial. Mol Ther 2017,25(12),2620-2634","journal-title":"Mol Ther"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/neuonc\/noq023","volume":"12","author":"Geletneky K.","year":"2010","unstructured":"Geletneky K.; Kiprianova I.; Ayache A.; Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro-oncol 2010,12(8),804-814","journal-title":"Neuro-oncol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1158\/1078-0432.CCR-10-3124","volume":"17","author":"Kiprianova I.","year":"2011","unstructured":"Kiprianova I.; Thomas N.; Ayache A.; Regression of glioma in rat models by intranasal application of parvovirus h-1. Clin Cancer Res 2011,17(16),5333-5342","journal-title":"Clin Cancer Res"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1471-2407-12-99","volume":"12","author":"Geletneky K.","year":"2012","unstructured":"Geletneky K.; Huesing J.; Rommelaere J.; Phase I\/IIa study of intratumoral\/intracerebral or intravenous\/intracerebral administration of parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 2012,12,99","journal-title":"BMC Cancer"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.ymthe.2004.07.021","volume":"10","author":"Chiocca E.A.","year":"2004","unstructured":"Chiocca E.A.; Abbed K.M.; Tatter S.; A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004,10(5),958-966","journal-title":"Mol Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/hum.2009.082","volume":"21","author":"Senac J.S.","year":"2010","unstructured":"Senac J.S.; Doronin K.; Russell S.J.; Jelinek D.F.; Greipp P.R.; Barry M.A.; Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther 2010,21(2),179-190","journal-title":"Hum Gene Ther"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3892\/or.2011.1306","volume":"26","author":"Zhang X.","year":"2011","unstructured":"Zhang X.; Zhao L.; Hang Z.; Guo H.; Zhang M.; Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines. Oncol Rep 2011,26(3),637-644","journal-title":"Oncol Rep"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2217\/fon.10.18","volume":"6","author":"Kanai R.","year":"2010","unstructured":"Kanai R.; Wakimoto H.; Cheema T.; Rabkin S.D.; Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol 2010,6(4),619-634","journal-title":"Future Oncol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12865-018-0281-9","volume":"19","author":"Ma W.","year":"2018","unstructured":"Ma W.; He H.; Wang H.; Oncolytic herpes simplex virus and immunotherapy. BMC Immunol 2018,19(1),40","journal-title":"BMC Immunol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-3-540-70617-5_11","volume":"330","author":"Russell S.J.","year":"2009","unstructured":"Russell S.J.; Peng K.W.; Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009,330,213-241","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1517\/14712598.2013.749851","volume":"13","author":"Msaouel P.","year":"2013","unstructured":"Msaouel P.; Opyrchal M.; Domingo Musibay E.; Galanis E.; Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther 2013,13(4),483-502","journal-title":"Expert Opin Biol Ther"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/sj.neo.7900016","volume":"1","author":"Chahlavi A.","year":"1999","unstructured":"Chahlavi A.; Todo T.; Martuza R.L.; Rabkin S.D.; Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1999,1(2),162-169","journal-title":"Neoplasia"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/78638","volume":"6","author":"Khuri F.R.","year":"2000","unstructured":"Khuri F.R.; Nemunaitis J.; Ganly I.; a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000,6(8),879-885","journal-title":"Nat Med"},{"key":"ref=97","first-page":"1666","volume":"23","author":"Xia Z.J.","year":"2004","unstructured":"Xia Z.J.; Chang J.H.; Zhang L.; [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus] Chin J Cancer 2004,23,1666-1670","journal-title":"Chin J Cancer"},{"key":"ref=98","first-page":"32","volume":"10","author":"Stanford M.M.","year":"2008","unstructured":"Stanford M.M.; Breitbach C.J.; Bell J.C.; McFadden G.; Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther 2008,10(1),32-37","journal-title":"Curr Opin Mol Ther"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/mt.2011.65","volume":"19","author":"Melcher A.","year":"2011","unstructured":"Melcher A.; Parato K.; Rooney C.M.; Bell J.C.; Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 2011,19(6),1008-1016","journal-title":"Mol Ther"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","volume":"39","author":"Gujar S.","year":"2018","unstructured":"Gujar S.; Pol J.G.; Kim Y.; Lee P.W.; Kroemer G.; Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies. Trends Immunol 2018,39(3),209-221","journal-title":"Trends Immunol"},{"key":"ref=101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"Zamarin D.","year":"2014","unstructured":"Zamarin D.; Holmgaard R.B.; Subudhi S.K.; Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014,6(226)","journal-title":"Sci Transl Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/mt.2014.160","volume":"22","author":"Engeland C.E.","year":"2014","unstructured":"Engeland C.E.; Grossardt C.; Veinalde R.; CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 2014,22(11),1949-1959","journal-title":"Mol Ther"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.1016\/j.vaccine.2010.07.066","volume":"28","author":"Sorensen M.R.","year":"2010","unstructured":"Sorensen M.R.; Holst P.J.; Steffensen M.A.; Christensen J.P.; Thomsen A.R.; Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 2010,28(41),6757-6764","journal-title":"Vaccine"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1158\/0008-5472.CAN-06-3974","volume":"67","author":"Diaz R.M.","year":"2007","unstructured":"Diaz R.M.; Galivo F.; Kottke T.; Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007,67(6),2840-2848","journal-title":"Cancer Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/hum.2009.143","volume":"21","author":"Galivo F.","year":"2010","unstructured":"Galivo F.; Diaz R.M.; Thanarajasingam U.; Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther 2010,21(4),439-450","journal-title":"Hum Gene Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1158\/0008-5472.CAN-09-4658","volume":"70","author":"Wongthida P.","year":"2010","unstructured":"Wongthida P.; Diaz R.M.; Galivo F.; Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 2010,70(11),4539-4549","journal-title":"Cancer Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1751-7915.2011.00296.x","volume":"5","author":"Altomonte J.","year":"2012","unstructured":"Altomonte J.; Ebert O.; Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol 2012,5(2),251-259","journal-title":"Microb Biotechnol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/mt.2015.156","volume":"24","author":"Rajani K.","year":"2016","unstructured":"Rajani K.; Parrish C.; Kottke T.; Combination therapy with reovirus and Anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther 2016,24(1),166-174","journal-title":"Mol Ther"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/scrt25","volume":"1","author":"Dwyer R.M.","year":"2010","unstructured":"Dwyer R.M.; Khan S.; Barry F.P.; O\u2019Brien T.; Kerin M.J.; Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther 2010,1(3),25","journal-title":"Stem Cell Res Ther"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/cgt.2010.4","volume":"17","author":"Garc\u00eda-Castro J.","year":"2010","unstructured":"Garc\u00eda-Castro J.; Alemany R.; Cascall\u00f3 M.; Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther 2010,17(7),476-483","journal-title":"Cancer Gene Ther"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","volume":"7","author":"Jain R.K.","year":"2010","unstructured":"Jain R.K.; Stylianopoulos T.; Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010,7(11),653-664","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.addr.2009.12.003","volume":"62","author":"Fisher K.D.","year":"2010","unstructured":"Fisher K.D.; Seymour L.W.; HPMA copolymers for masking and retargeting of therapeutic viruses. Adv Drug Deliv Rev 2010,62(2),240-245","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijpharm.2007.08.025","volume":"354","author":"Eto Y.","year":"2008","unstructured":"Eto Y.; Yoshioka Y.; Mukai Y.; Okada N.; Nakagawa S.; Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm 2008,354(1-2),3-8","journal-title":"Int J Pharm"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrc1958","volume":"6","author":"Duncan R.","year":"2006","unstructured":"Duncan R.; Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006,6(9),688-701","journal-title":"Nat Rev Cancer"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/sj.mt.6300363","volume":"16","author":"Morrison J.","year":"2008","unstructured":"Morrison J.; Briggs S.S.; Green N.; Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol Ther 2008,16(2),244-251","journal-title":"Mol Ther"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jconrel.2015.10.009","volume":"219","author":"Choi J.W.","year":"2015","unstructured":"Choi J.W.; Lee Y.S.; Yun C.O.; Kim S.W.; Polymeric oncolytic adenovirus for cancer gene therapy. J Control Release 2015,219,181-191","journal-title":"J Control Release"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"15018","DOI":"10.1038\/mto.2015.18","volume":"2","author":"Ruf B.","year":"2015","unstructured":"Ruf B.; Lauer U.M.; Assessment of current virotherapeutic application schemes: \u201chit hard and early\u201d versus \u201ckilling softly\u201d? Mol Ther Oncolytics 2015,2,15018","journal-title":"Mol Ther Oncolytics"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","volume":"31","author":"Yang L.","year":"2010","unstructured":"Yang L.; Pang Y.; Moses H.L.; TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010,31(6),220-227","journal-title":"Trends Immunol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/leu.2012.70","volume":"26","author":"Naik S.","year":"2012","unstructured":"Naik S.; Nace R.; Federspiel M.J.; Barber G.N.; Peng K.W.; Russell S.J.; Curative one-shot systemic virotherapy in murine myeloma. Leukemia 2012,26(8),1870-1878","journal-title":"Leukemia"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.ymthe.2017.05.006","volume":"25","author":"Durham N.M.","year":"2017","unstructured":"Durham N.M.; Mulgrew K.; McGlinchey K.; Oncolytic VSV primes differential responses to immuno-oncology therapy. Mol Ther 2017,25(8),1917-1932","journal-title":"Mol Ther"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/v10020090","volume":"10","author":"Bishnoi S.","year":"2018","unstructured":"Bishnoi S.; Tiwari R.; Gupta S.; Byrareddy S.N.; Nayak D.; Oncotargeting by vesicular stomatitis virus (VSV): advances in cancer therapy. Viruses 2018,10(2),10","journal-title":"Viruses"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1006\/mthe.2001.0448","volume":"4","author":"Carew J.F.","year":"2001","unstructured":"Carew J.F.; Kooby D.A.; Halterman M.W.; Kim S.H.; Federoff H.J.; Fong Y.; A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther 2001,4(3),250-256","journal-title":"Mol Ther"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41467-017-01385-8","volume":"8","author":"Wang P.","year":"2017","unstructured":"Wang P.; Li X.; Wang J.; Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun 2017,8(1),1395","journal-title":"Nat Commun"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1158\/0008-5472.CAN-08-1160","volume":"69","author":"Edukulla R.","year":"2009","unstructured":"Edukulla R.; Woller N.; Mundt B.; Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res 2009,69(4),1448-1458","journal-title":"Cancer Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/CJI.0b013e318193d31e","volume":"32","author":"Lapteva N.","year":"2009","unstructured":"Lapteva N.; Aldrich M.; Weksberg D.; Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother 2009,32(2),145-156","journal-title":"J Immunother"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1126\/scitranslmed.aam7577","volume":"10","author":"Samson A.","year":"2018","unstructured":"Samson A.; Scott K.J.; Taggart D.; Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med 2018,10(422),10","journal-title":"Sci Transl Med"},{"key":"ref=127","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1220467","volume":"5","author":"Kleinpeter P.","year":"2016","unstructured":"Kleinpeter P.; Fend L.; Thioudellet C.; Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. OncoImmunology 2016,5(10)","journal-title":"OncoImmunology"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T10:35:23Z","timestamp":1581071723000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176359\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":127,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2020,1,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666191104090544","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}